GlobalData Plc

The rheumatoid arthritis space across the eight major markets (8MM) of the US, France, Germany, Italy, Spain, the UK, Japan, and Australia, is set to grow from $19.5 billion in 2015 to around $28.5 billion by 2025, representing a compound annual growth rate of 3.9%, according to GlobalData, a recognized leader in providing business information and analytics.

The company’s latest report states that major growth drivers include an increase of prevalent rheumatoid arthritis cases, the anticipated introduction of interleukin (IL)-6 inhibitors, the launch and continued uptake of biosimilars for all established biologics on the market, and the early diagnosis and treatment of patients with the disease to limit progression.

Kavita Rainova, MSc, Senior Healthcare Analyst at GlobalData, explains: “Biosimilars for all established biologics are expected to launch in all 8MM by 2025, with the exception of etanercept in the US and certolizumab in Japan. Overall, biosimilars will account for 23% of the market by 2025.

“Big Pharma companies such as Pfizer and Amgen are aware of the commercial potential of these products, and as such are pursuing their own biosimilar development programs.”

The other drug class that is expected to command noteworthy market share is that of Janus Kinase (JAK) inhibitors. The uptake of Pfizer’s Xeljanz, the only JAK inhibitor currently available for rheumatoid arthritis had been low initially due to certain safety concerns, with primary research conducted by GlobalData indicating that rheumatologists reserve Xeljanz for fourth-line therapy.

Even so, sales of the drug are expected to rise in the first half of the forecast, partly due to increased familiarity with the drug by physicians, as well as its potential launch in the EU. Apart from Xeljanz, four other JAK inhibitors are expected to launch during the forecast period: Eli Lilly/Incyte’s baricitinib, Astellas’ peficitinib, AbbVie’s upadacitinib, and Galapagos/Gilead’s filgotinib.

Rainova continues: “Although available biologic agents are reasonably effective at managing the symptoms of rheumatoid arthritis and preventing disease progression, the challenges of treating the disease lie in the unpredictable responses of each patient, representing one of the biggest unmet needs in the market.

“Unmet needs are likely to be addressed through initiatives and research efforts to understand the pathophysiology of rheumatoid arthritis, and through the development of biomarkers for the disease. While research in this area is underway, it is expected that individualized medicine will still be in its initial stages by 2025.”

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF